Obe­si­ty drug race heats up as In­novent un­corks new GLP1 da­ta

While Eli Lil­ly has been hy­per-fo­cused on de­thron­ing No­vo Nordisk’s semaglu­tide in the di­a­betes and obe­si­ty space, an­oth­er chal­lenger sneaked up from be­hind.

In­novent Bi­o­log­ics burst on­to the scene Tues­day with Phase II da­ta show­ing its GLP-1 re­cep­tor/glucagon re­cep­tor dual ag­o­nist re­duced pa­tients’ body weights by more than 12% at the high­est dose com­pared to place­bo.

The obe­si­ty study en­rolled 248 Chi­nese par­tic­i­pants with 230 com­plet­ing a full 24 weeks of treat­ment on ei­ther vary­ing dos­es of once-week­ly maz­du­tide in­jec­tions or place­bo. At the high­est 6-mg dose, maz­du­tide pa­tients saw an 11.57% re­duc­tion in body weight from base­line, com­pared to the 1.05% re­duc­tion seen by place­bo pa­tients (p < 0.0001). That com­pares to a 7.21% re­duc­tion from base­line on the low­est dose, 3 mg.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER